Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Status:
Terminated
Trial end date:
2019-07-30
Target enrollment:
Participant gender:
Summary
This study is being done to determine if there is a potential benefit of saracatinib in LAM
subjects. Based on the information of this trial, additional clinical development trials will
be needed. The study will also test the tolerability of 125 mg of saracatinib given once
daily over a 9 month period.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Brigham and Women's Hospital Loyola University National Institutes of Health (NIH) Stanford University University of Cincinnati University of South Florida